ADIENNE Pharma & Biotech Signs Service Agreement with Selexis for the Development of a Novel Fully Human Mini-Antibody

ADIENNE Pharma & Biotech has entered into a Service Agreement with Selexis for the rapid development of a manufacturing cell line for one of ADIENNE’s orphan drugs .

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
Combining our expertise in difficult-to-express proteins with our SUREtechnology Platform™ is an important step in advancing ADIENNE’s project to the clinic.

Geneva, Switzerland (PRWEB) May 15, 2012

Selexis SA , a global life sciences company for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins, announced today that ADIENNE Pharma & Biotech has entered into a Service Agreement with Selexis for the rapid development of a manufacturing cell line for one of ADIENNE’s orphan drugs .

"We are very pleased that ADIENNE has chosen to use Selexis for the development of its molecule," said Igor Fisch, PhD, CEO of Selexis SA. “Combining our expertise in difficult-to-express proteins with our SUREtechnology Platform™ is an important step in advancing ADIENNE’s project to the clinic.”

"Selexis expertise will be an added value for our molecule,” said Antonio Francesco Di Naro, PhD, Founder and CEO of ADIENNE Pharma & Biotech. “This collaboration will be fruitful for our company.”

About Selexis SA
Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with innovative technologies and world-class expert services for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins. The Company's SUREtechnology Platform™ is based on Selexis Genetic Elements™ -- novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. Selexis has generated over 1,300 cell lines being used in a variety of programs from drug discovery to late-stage clinical trials. The Company anticipates three products manufactured from cell lines using the Selexis SUREtechnology Platform™ to be launched in 2012.

For more information:

About ADIENNE
ADIENNE is a dynamic pharma and biotech company dedicated to the treatment of rare and severe diseases. It is located in Bergamo (Italy) and operates both in the European and in the International pharmaceutical market. ADIENNE’s mission is to satisfy unmet clinical needs. Within the frame of challenging and life threatening clinical pathologies, the company develops biological orphan drugs products from research to commercialization in onco-haematology, autoimmune diseases, solid organ and bone marrow transplantation. ADIENNE is involved in biotechnology research and production, holding its own laboratories and manufacturing site, with fully integrated scientific, regulatory, pharmacovigilance, clinical, medical and commercial structures.

For more information:


Contact

Follow us on: Contact's Facebook Contact's Twitter Contact's LinkedIn

Attachments

Selexis Corporate Logo